Considerations for supplementing with coenzyme Q10 during statin therapy

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 290-294

  Levy, Hedva Barenholtz ^a,b,c   Kohlhaas, Heather K ^b  

^a UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c NONE   (United States)

Author keywords

HMG CoA reductase inhibitors; Statins; Ubiquinone

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; CERIVASTATIN; COLESTYRAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; UBIDECARENONE;

ANGINA PECTORIS; ANOREXIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DIASTOLE; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG PENETRATION; ENZYME BLOOD LEVEL; EPIGASTRIC DISCOMFORT; FAMILIAL HYPERCHOLESTEROLEMIA; HEART FAILURE; HIGH RISK POPULATION; HUMAN; MITOCHONDRIAL RESPIRATION; MUSCLE BIOPSY; MUSCLE TOXICITY; MYOPATHY; NAUSEA; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TOXICITY; TREATMENT DURATION;

EID: 33144464458     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G409     Document Type: Review

References (33)

1. 10. Am J Health Syst Pharm 1999;56:519-21.
2. 10. J Am Coll Nutr 2001;20:591-8.
3. Hargreaves IP, Heales S. Statins and myopathy. Lancet 2002;359:711-2.
4. Hume AL. Comment: lovastatin-induced rhabdomyolysis in the absence of concomitant drugs (letter). Ann Pharmacother 1992;26:1303.
5. Ernster L, Forsmark-Andree P. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Invest 1993;71(suppl):S60-5.
6. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990;87:8931-4.
7. 10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9.
8. Palomaki A, Malminiemi K, Solakivi T, Malminieme O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 1998;39:1430-7.
9. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994;46:313-7.
10. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of state. J Am Coll Cardiol 2002;40:567-71.
11. 10. The Baycol case - a modern Pandora's box. Biomed Pharmacother 2002;56:56-9.
12. 10. Lancet 2003;361:1134-5.
13. Koumis R, Nathan JP, Rosenberg JM, Cicero LA. Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation? Am J Health Syst Pharm 2004;61:515-9.
14. 10. A review of animal and human publications. Biofactors 2003;18:101-11.
15. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993;46:1055-7.
16. Elmberger PG, Kalen A, Lund E, et al. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991;32:935-40.
17. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-4.
18. Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005;12:111-9.
19. 10. Am Heart J 2001;142:e2.
20. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333-7.
21. Human JA, Ubbink JB, Jerling JJ, et al. The effect of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 1997;263:67-77.
22. Appelkvist EL, Edlund C, Low P, Schedin S, Kalen A, Dallner G. Effects of inhibitors of hydroxymethylglutaryl coenzyme A reductase on coenzyme Q and dolichol biosynthesis. Clin Investig 1993;71(suppl):S97-102.
23. Päivä H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005;78:60-8.
24. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5.
25. 10 level in statin-related myopathy. Arch Neurol 2005;62:1709-12.
26. 10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Molec Aspects Med 1994;15(suppl):S187- 93.
27. Lankin VZ, Konovalova GG, Tikhaze AK, Nezhdanova IB, Olfer'ev AM, Kukkarchuk VV. Oxidation of plasma low-density lipoproteins from coronary patients with various forms of hypercholesterolemia. Bull Exp Biol Med 2003;136:2-5.
28. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-73.
29. 10 to reverse that dysfunction. Am J Cardiol 2004;94:1306-10.
30. 10 and congestive heart failure: what is the verdict? Can J Cardiol 2002;18:1054-8.
31. 10 in heart failure. Ann Pharmacother 2005;39:1522-6. Epub 26 Jul 2005. DOI 10.1345/aph.1E554
32. Farmer JA. Learning from the cerivastatin experience. Lancet 2001;358:1383-4.
33. 10. In: Forget L, ed. Herbal companion to AHFS DI 2001. Bethesda, MD: American Society of Health-System Pharmacists, 2000.